Rosacea, Subtypes, Triggers, and What Research Suggests May Calm It

The four subtypes

• Erythematotelangiectatic (ETR), persistent central facial redness and visible vessels.
• Papulopustular, redness plus inflammatory papules and pustules; often confused with acne.
• Phymatous, thickening of skin, particularly nasal (rhinophyma), more common in men.
• Ocular, eye involvement, gritty sensation, redness; commonly underdiagnosed.

What research suggests is happening

Rosacea involves dysregulated innate immune signaling, particularly through cathelicidin antimicrobial peptide LL-37, and vascular hyperreactivity. The Demodex mite, a normal skin resident, is present in higher density on rosacea-affected skin and may contribute to inflammation. UV exposure, temperature shifts, and certain dietary triggers exacerbate the picture.

Common triggers

• Sun exposure, the most consistent trigger.
• Heat, hot drinks, hot showers, hot weather.
• Spicy food and alcohol, particularly red wine.
• Stress and emotional flushing.
• Aerobic exercise, heat plus circulation.
• Certain skincare ingredients, fragrance, menthol, camphor, alcohol-based toners.
• Wind and extreme cold.

What research supports, over-the-counter and lifestyle

• Trigger identification and avoidance, the highest-leverage starting point.
• Daily mineral SPF, non-negotiable.
• Gentle, fragrance-free, barrier-supportive routine.
• Niacinamide 2–5%, research suggests redness reduction.
• Centella asiatica / madecassoside, well-studied calming evidence.
• Green tea polyphenols, antioxidant and calming.
• Avoidance of physical exfoliants and aggressive actives.

What research supports, prescription (dermatology)

• Metronidazole topical, established first-line for papulopustular rosacea.
• Azelaic acid 15% (prescription strength).
• Ivermectin 1% topical, research suggests action against Demodex.
• Brimonidine and oxymetazoline topicals, vasoconstrictive for redness.
• Oral doxycycline at sub-antimicrobial doses, anti-inflammatory effect.
• Vascular laser and IPL, for persistent vessels.

Timeline

Trigger management produces results within weeks. Topical prescriptions typically show measurable improvement at 8 to 12 weeks. Vascular treatments are procedural and offer faster results for visible vessels. Research suggests rosacea is a chronic condition requiring ongoing management, not a one-time clearing.